Unifying Interpretability and Explainability for Alzheimer's Disease Progression Prediction
0
🔮
Sign in to get full access
Overview
- Reinforcement learning (RL) has shown promise in predicting Alzheimer's disease (AD) progression, but it's unclear which RL algorithms are best suited for this task.
- RL methods are not inherently explainable, limiting their real-world applicability in clinical scenarios.
- This work compares the performance of four RL algorithms in predicting brain cognition over 10 years, and applies SHAP to explain the decisions made by each algorithm.
- The approach aims to combine predictive accuracy with transparency, to provide insights into the key factors influencing AD progression, both globally and at the individual patient level.
Plain English Explanation
Alzheimer's disease is a complex and devastating condition that affects memory and cognitive function. Researchers have been exploring the use of reinforcement learning, a type of artificial intelligence, to help predict how Alzheimer's might progress in individual patients. This is a promising approach, as reinforcement learning can model the intricate relationships between different factors that contribute to the disease.
However, the specific reinforcement learning algorithms that work best for Alzheimer's prediction are not yet clear. Additionally, these algorithms can be like "black boxes" – it's not always easy to understand how they arrive at their predictions. This can be a problem in real-world medical settings, where doctors and patients need to trust the reasoning behind the AI's recommendations.
In this study, the researchers address these two key issues. First, they compare the performance of four different reinforcement learning algorithms in predicting changes in brain cognition over 10 years, using only baseline (starting) data for each patient. Then, they apply a technique called SHAP to explain the reasoning behind the predictions made by each algorithm.
By combining predictive power with transparency, the researchers aim to provide valuable insights into the factors that drive Alzheimer's disease progression. This could help clinicians and researchers make more informed decisions about patient care and disease management.
Technical Explanation
The researchers used a causal, interpretable model of Alzheimer's disease to compare the performance of four contemporary reinforcement learning (RL) algorithms in predicting brain cognition over a 10-year period. The algorithms were trained using only baseline (year 0) data for each patient.
To provide explanations for the algorithms' predictions, the researchers applied SHAP, a technique that can explain the individual-level decisions made by machine learning models. This allowed the researchers to gain insights into the key factors influencing Alzheimer's disease progression, both at a global and individual patient level.
The findings showed that only one of the RL methods was able to satisfactorily model disease progression. However, the post-hoc explanations revealed that all the algorithms failed to properly capture the importance of amyloid accumulation, which is a hallmark pathological feature of Alzheimer's disease.
Critical Analysis
The researchers acknowledge that their work has some limitations. For instance, the causal model of Alzheimer's disease used in the study may not fully capture the complex, multifactorial nature of the disease. Additionally, the researchers note that the performance of the RL algorithms could be improved by incorporating more diverse data sources, such as multimodal biomarkers or self-explainable graph neural networks.
Further research is also needed to better understand the factors that influence the RL algorithms' decision-making processes, and to assess the significance of longitudinal data in Alzheimer's disease forecasting. By continuing to explore the integration of predictive accuracy and model interpretability, the researchers can work towards developing more transparent and trustworthy AI systems for Alzheimer's disease management.
Conclusion
This study takes an important step towards merging predictive accuracy with transparency in the context of Alzheimer's disease progression modeling. By comparing the performance of different reinforcement learning algorithms and applying SHAP to explain their decisions, the researchers have provided valuable insights into the key factors influencing Alzheimer's disease. This work can assist clinicians and researchers in making more informed healthcare decisions, and paves the way for further development of explainable AI systems in the field of Alzheimer's disease management.
This summary was produced with help from an AI and may contain inaccuracies - check out the links to read the original source documents!
Related Papers
🔮
0
Unifying Interpretability and Explainability for Alzheimer's Disease Progression Prediction
Raja Farrukh Ali, Stephanie Milani, John Woods, Emmanuel Adenij, Ayesha Farooq, Clayton Mansel, Jeffrey Burns, William Hsu
Reinforcement learning (RL) has recently shown promise in predicting Alzheimer's disease (AD) progression due to its unique ability to model domain knowledge. However, it is not clear which RL algorithms are well-suited for this task. Furthermore, these methods are not inherently explainable, limiting their applicability in real-world clinical scenarios. Our work addresses these two important questions. Using a causal, interpretable model of AD, we first compare the performance of four contemporary RL algorithms in predicting brain cognition over 10 years using only baseline (year 0) data. We then apply SHAP (SHapley Additive exPlanations) to explain the decisions made by each algorithm in the model. Our approach combines interpretability with explainability to provide insights into the key factors influencing AD progression, offering both global and individual, patient-level analysis. Our findings show that only one of the RL methods is able to satisfactorily model disease progression, but the post-hoc explanations indicate that all methods fail to properly capture the importance of amyloid accumulation, one of the pathological hallmarks of Alzheimer's disease. Our work aims to merge predictive accuracy with transparency, assisting clinicians and researchers in enhancing disease progression modeling for informed healthcare decisions. Code is available at https://github.com/rfali/xrlad.
Read more6/13/2024
0
Learning the irreversible progression trajectory of Alzheimer's disease
Yipei Wang, Bing He, Shannon Risacher, Andrew Saykin, Jingwen Yan, Xiaoqian Wang
Alzheimer's disease (AD) is a progressive and irreversible brain disorder that unfolds over the course of 30 years. Therefore, it is critical to capture the disease progression in an early stage such that intervention can be applied before the onset of symptoms. Machine learning (ML) models have been shown effective in predicting the onset of AD. Yet for subjects with follow-up visits, existing techniques for AD classification only aim for accurate group assignment, where the monotonically increasing risk across follow-up visits is usually ignored. Resulted fluctuating risk scores across visits violate the irreversibility of AD, hampering the trustworthiness of models and also providing little value to understanding the disease progression. To address this issue, we propose a novel regularization approach to predict AD longitudinally. Our technique aims to maintain the expected monotonicity of increasing disease risk during progression while preserving expressiveness. Specifically, we introduce a monotonicity constraint that encourages the model to predict disease risk in a consistent and ordered manner across follow-up visits. We evaluate our method using the longitudinal structural MRI and amyloid-PET imaging data from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Our model outperforms existing techniques in capturing the progressiveness of disease risk, and at the same time preserves prediction accuracy.
Read more9/2/2024
🤿
0
Multimodal hierarchical multi-task deep learning framework for jointly predicting and explaining Alzheimer disease progression
Sayantan Kumar, Sean Yu, Andrew Michelson, Thomas Kannampallil, Philip Payne
Objective: We aimed to develop and validate a novel multimodal framework HiMAL (Hierarchical, Multi-task Auxiliary Learning) framework, for predicting cognitive composite functions as auxiliary tasks that estimate the longitudinal risk of transition from Mild Cognitive Impairment (MCI) to Alzheimer Disease (AD). Methods: HiMAL utilized multimodal longitudinal visit data including imaging features, cognitive assessment scores, and clinical variables from MCI patients in the Alzheimer Disease Neuroimaging Initiative (ADNI) dataset, to predict at each visit if an MCI patient will progress to AD within the next 6 months. Performance of HiMAL was compared with state-of-the-art single-task and multi-task baselines using area under the receiver operator curve (AUROC) and precision recall curve (AUPRC) metrics. An ablation study was performed to assess the impact of each input modality on model performance. Additionally, longitudinal explanations regarding risk of disease progression were provided to interpret the predicted cognitive decline. Results: Out of 634 MCI patients (mean [IQR] age : 72.8 [67-78], 60% men), 209 (32%) progressed to AD. HiMAL showed better prediction performance compared to all single-modality singe-task baselines (AUROC = 0.923 [0.915-0.937]; AUPRC= 0.623 [0.605-0.644]; all p<0.05). Ablation analysis highlighted that imaging and cognition scores with maximum contribution towards prediction of disease progression. Discussion: Clinically informative model explanations anticipate cognitive decline 6 months in advance, aiding clinicians in future disease progression assessment. HiMAL relies on routinely collected EHR variables for proximal (6 months) prediction of AD onset, indicating its translational potential for point-of-care monitoring and managing of high-risk patients.
Read more5/7/2024
0
An interpretable generative multimodal neuroimaging-genomics framework for decoding Alzheimer's disease
Giorgio Dolci (Department of Engineering for Innovation Medicine, University of Verona, Verona, Italy, Tri-Institutional Center for Translational Research in Neuroimaging and Data Science), Federica Cruciani (Department of Engineering for Innovation Medicine, University of Verona, Verona, Italy), Md Abdur Rahaman (Tri-Institutional Center for Translational Research in Neuroimaging and Data Science), Anees Abrol (Tri-Institutional Center for Translational Research in Neuroimaging and Data Science), Jiayu Chen (Tri-Institutional Center for Translational Research in Neuroimaging and Data Science), Zening Fu (Tri-Institutional Center for Translational Research in Neuroimaging and Data Science), Ilaria Boscolo Galazzo (Department of Engineering for Innovation Medicine, University of Verona, Verona, Italy), Gloria Menegaz (Department of Engineering for Innovation Medicine, University of Verona, Verona, Italy), Vince D. Calhoun (Tri-Institutional Center for Translational Research in Neuroimaging and Data Science)
Alzheimer's disease (AD) is the most prevalent form of dementia with a progressive decline in cognitive abilities. The AD continuum encompasses a prodormal stage known as Mild Cognitive Impairment (MCI), where patients may either progress to AD or remain stable. In this study, we leveraged structural and functional MRI to investigate the disease-induced grey matter and functional network connectivity changes. Moreover, considering AD's strong genetic component, we introduce SNPs as a third channel. Given such diverse inputs, missing one or more modalities is a typical concern of multimodal methods. We hence propose a novel deep learning-based classification framework where generative module employing Cycle GANs was adopted to impute missing data within the latent space. Additionally, we adopted an Explainable AI method, Integrated Gradients, to extract input features relevance, enhancing our understanding of the learned representations. Two critical tasks were addressed: AD detection and MCI conversion prediction. Experimental results showed that our model was able to reach the SOA in the classification of CN/AD reaching an average test accuracy of $0.926pm0.02$. For the MCI task, we achieved an average prediction accuracy of $0.711pm0.01$ using the pre-trained model for CN/AD. The interpretability analysis revealed significant grey matter modulations in cortical and subcortical brain areas well known for their association with AD. Moreover, impairments in sensory-motor and visual resting state network connectivity along the disease continuum, as well as mutations in SNPs defining biological processes linked to amyloid-beta and cholesterol formation clearance and regulation, were identified as contributors to the achieved performance. Overall, our integrative deep learning approach shows promise for AD detection and MCI prediction, while shading light on important biological insights.
Read more6/21/2024